Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2026-06-05 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 2 pages 298.3KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3Z Final Director’s Interest Notice under Listing Rule 3.19A.3, detailing a director’s relevant interests in securities (number and class of shares). This corresponds to a director’s personal share dealings disclosure rather than a broader financial report, fitting the definition of Director’s Dealing (code DIRS).
2026-06-05 English
Mayne Pharma receives $14.4m for legal costs from Cosette 2 pages 161.2KB
Legal Proceedings Report Classification · 90% confidence The document is an ASX announcement providing an update on a court proceeding and the receipt of legal costs following a Supreme Court order. It directly relates to ongoing litigation against Cosette, detailing court judgments and costs recovery. This fits the definition of a Legal Proceedings Report (Code: LTR), which covers updates on significant lawsuits or legal matters.
2026-06-05 English
MYX Jefferies Global Healthcare Conference Presentation 25 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement that provides an investor presentation to be delivered at the Jefferies Global Healthcare Conference. It contains slides with corporate summary, financial highlights, strategic overview, and other investor‐focused materials. This matches the definition of an Investor Presentation (Code: IP).
2026-06-04 English
New DistributeRx partnership with Resilia Pharmaceuticals 2 pages 161.7KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement detailing a commercial distribution partnership between Mayne Pharma’s subsidiary and Resilia Pharmaceuticals. It provides no financial results, no AGM materials, no management or board changes, no capital/fundraising activity, dividends, share issues, or other specific categories. It is a routine regulatory announcement (press release) filed with the exchange that does not fit the specialized categories, so it falls under the general Regulatory Filings (RNS) category.
2026-06-01 English
Mayne Pharma to present at Jefferies Healthcare Conference 1 page 113.4KB
Report Publication Announcement Classification · 75% confidence The document is a brief ASX announcement about an upcoming investor presentation at a conference and notes that “a copy of the presentation will be lodged to ASX” prior to the event. It does not contain the presentation itself or substantive financial data; instead it simply notifies investors of the forthcoming release of a presentation. Under the “menu vs. meal” rule for distinguishing announcements of report/publication from the report itself, this is a report publication announcement (RPA).
2026-05-26 English
Court awards MYX $13.27m for legal costs from Cosette 2 pages 162.3KB
Legal Proceedings Report Classification · 92% confidence The document is a public ASX announcement detailing the outcome of legal proceedings in which Mayne Pharma was awarded legal costs by the Supreme Court. It provides an update on a significant lawsuit and court judgment, with no financial report data or meeting details. This fits squarely into the Legal Proceedings Report category.
2026-05-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.